HUTCHMED Initiates a Phase Ib/II Trial of Surufatinib in Combination with Tislelizumab in Patients with Advanced Solid Tumors

NEXT STORY
ANNOUNCES THE LAUNCH OF 3B FUTURE HEALTH FUND II
PREV STORY
Basilea reports positive interim results from phase 2 study FIDES-01 for derazantinib in FGFR2 gene mutation- or amplification-positive patients with bile duct cancer (iCCA)
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Bavarian Nordic offentliggør yderligere positive data fra fase 2 forsøg med selskabets vaccine mod RS-virus

Tilstedeværelsen af antistoffer i næseslimhinderne indikerer vaccinefremkaldt beskyttelse på infektionsstedet IgA antistoffer mod RS-virus ...

author_avatar
NASDAQ Market News

Incysus Announces FDA Approval of IND Application for a Phase 1 Study of a Gamma-Delta (γδ) T Cell Leukemia and Lymphoma Immunotherapy

--  First Clinical Trial to Test the Safety and Activity of Activated Allogeneic Donor ...

author_avatar
NASDAQ Market News

A comprehensive eye exam can do more than test your vision – it could help save your life

OTTAWA, May 2, 2016 (GLOBE NEWSWIRE) -- May is Vision Health Month, and doctors ...

author_avatar
NASDAQ Market News